News | May 03, 2025
RPG Life Sciences posts Q4 FY25 net profit at Rs. 117.35 Cr
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The Q1 2025 also witnessed a successful launch of Allegra D
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
